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ABSTRACT
Following recent regional court decisions on the
infringement of second medical use patent claims, the
German concept of manifest arrangement—previously
believed to provide a safe harbor for generic pharmaceutical
companies as long as they skinny-labeled their products—
may be subject to a new interpretation. The German
decisions are part of a Europe wide series of decisions on
the same or similar subject matter and prove to be patent
owner friendly.1

*

Dr. Matthias Zigann, Presiding Judge, Munich Regional Court I, 7 th (Patent)
Division, Munich, Germany.
1
Denmark; http://kluwerpatentblog.com/2015/08/06/pregabalin-secondmedical-use-claims-construction-in-denmark/; England & Wales: Generics
(UK) Ltd (t/a Mylan) v Warner-Lambert Company LLC [2015] EWHC
2548 (Pat); France: http://ipkitten.blogspot.de/2015/11/vive-la-differenceno-need-for.html Spain:
http://www.internationallawoffice.com/Newsletters/IntellectualProperty/Spain/Grau-Angulo/Court-dismisses-preliminary-injunctionapplication-in-pregabalin-patent-case#decision; The Netherlands: Novartis
AG v Sun Pharmaceutical Industries (Europe) BV C/09/460540 / KG ZA;
Warner-Lambert Company LLC v. the State of The Netherlands (Dutch
Medicines Evaluation Board), District Court of The Hague, The
Netherlands, 15 January 2016, Case file number: C/09/498943 / KG ZA 151656.
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INTRODUCTION
In 2000, Swiss-type second medical use patent claims (e.g. “use
of x for the manufacture of a medicament to cure illness y”)2 were
invented to overcome or circumvent the exclusion from patentability
of methods to cure the human body as laid down in the original Art.
52 (4) EPC.3 Since then, discussion has arisen about the new scope
of protection for such claims. Particular attention has gone to
distinguishing competitive legal behavior—which could be aimed at
the production, distribution, and application of a medicament
intended to cure the first now-unpatented indication—from illegal
behavior aimed at the production, distribution, and application of the
same medicament to cure a second patented indication.4
Recently confirmed5 decisions6 by the Federal Court of
Justice found that the manifest arrangement of a medicament for the
second medical use already constitutes a second medical use. In
answer, the lower infringement courts granted injunctions against
competitors for direct patent infringement, pursuant to Sec. 9
2

According to legal advice given by the Swiss Patent Office in May 1984, these
are called Swiss Type Claims.
3
Revision entered into force on 13 December 2007.
4
Königer/Kompter/Ludwig/Lunze/Prinz zu Waldeck und Pyrmont/
Schüssler/Wiegeleben GRUR Int. 2014, 906.
5
Federal Court of Justice IBRR3 2016, 1909 – Pemetrexed [#83-88]. The
Federal Court of Justice has indicated in that decision that a Swiss-type
claim may provide the same purpose limited substance protection as a
purpose limited substance claim does. The finding is however not final as
the case has been sent back to the lower court for further consideration.
6
Federal Court of Justice GRUR 1983, 729, 730/731– Hydropyridin; GRUR
2001, 730, 730/731 – Trigonellin.
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German Patent Act,7 if they manifestly arranged their product for
the second medical use.8 Processes such as making into a confection
ready-to-use preparation, dosage, label instructions (as closely
linked to the manufacturing process) or otherwise arranging the
product were found to be manifest arrangements, especially if
designed for a second medical use. The question as to whether the
manifestly arranged product was later in fact used for the second
indication was of no importance.9 However, other activities—like
general announcements in marketing materials, flyers, and
advertisements or indications given by sales people—were held
insufficient to constitute a manifest arrangement, as they were found
to be not related closely enough to the product or package.10 The socalled “skinny labeling” proved to be a way for the competitor to
avoid allegations of direct patent infringement, even when the
product was later used for its second indication11. As a result, patent
owners raised fewer allegations of indirect patent infringement

7

A patent shall have the effect that the patentee alone shall be authorized to use
the patented invention. A person not having the consent of the patentee shall
be prohibited 1. from making, offering, putting on the market or using a
product which is the subject matter of the patent or importing or stocking
the product for such purposes; 2. from using a process which is the subject
matter of the patent or, when he knows or it is obvious from the
circumstances that the use of the process is prohibited without the consent
of the patentee, from offering the process for use within the territory to
which this Law applies; 3. from offering, putting on the market, using or
importing or stocking for such purposes the product obtained directly by a
process which is the subject matter of the patent.
8
Regional Court Düsseldorf GRUR-RR 2004, 193 – Ribavirin.
9
Regional Court Düsseldorf GRUR-RR 2004, 193 – Ribavirin.
10
Regional Court Düsseldorf –Ribavirin“, 24 February 2004 – 4a O 12/03,
BeckRS 2004, 05148; Higher Regional Court Düsseldorf - “Cistus
Incanus”, 31 January 2013 – I-2 U 53/11, BeckRS 2013, 03824; Higher
Regional Court Düsseldorf - “Cistus Incanus”, 31 January 2013 – I-2 U
54/11; BeckRS 2013, 11782; Regional Court Düsseldorf - “Chronische
Hepatitis C”, 14 March 2013 – 4a O 145/12, Düsseldorfer Entscheidungen
No. 2011.
11
Higher Regional Court Düsseldorf BeckRS 2013, 11782 – Cistus Incanus;
Regional Court Düsseldorf, Case No. 4 a O 145/12, decision of 14 March
2013 –- Chronische Hepatitis C.
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pursuant to Sec. 10 of the German Patent Act.12 Notably, this was
because patent owners could not prove that the competitor knew that
the customer was inclined to use the product for the second
indication and not the first.
I. THE HAMBURG REGIONAL COURT`S DECISION
However, recent decisions by the Hamburg Regional Court13 in
five parallel preliminary proceedings may have taken away the “safe
harbor” of skinny labeling, particularly in the context of rebate
agreements.
A. Factual Circumstances
The second medical use patent in suit covered the use of
Pregabalin for the preparation of a pharmaceutical composition for
treating pain. The defendants, pharmaceutical companies, produced
a medicament for the (patent-free) first medical uses of
Pregabalin—namely, to treat epilepsy and generalized anxiety
disorder.14 The labels did not mention pain as an indication and there
was no advertisement or marketing activity in that direction. After
tender procedures for providing Pregabalin in large quantities to
public health insurers, the defendants entered into
rebate
agreements with these health insurers. The rebate agreements were
silent on the intended medical uses; in particular, they did not carve
12

A patent shall have the further effect that a person not having the consent of
the patentee shall be prohibited from supplying or offering to supply within
the territory to which this Law applies a person, other than a person entitled
to exploit the patented invention, with means relating to an essential
element of such invention for exploiting the invention, where such person
knows or it is obvious from the circumstances that such means are suitable
and intended for exploiting the invention.
13
2 April 2015 – 327 O 67/15; BeckRS 2015, 08240; GRUR-RR 2015, 330; 4
out auf 5 parallel preliminary injunctions have become final. One appeal is
still pending, an oral hearing (case no. 3 U 91/15) scheduled for July 28,
2016 has been postponed to February 2017 to await the outcome of pending
nullity proceedings.
14
2 April 2015 – 327 O 67/15; BeckRS 2015, 08240; GRUR-RR 2015, 330;
appeal is pending, an oral hearing is scheduled for July 28, 2016.
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out the use of Pregabalin to be provided to treat pain.15
Sec. 130a (8) of the German Social Law Book V provides for
the possibility of health insurers entering into such rebate
agreements with pharmaceutical companies. Sec. 129 (1) of that law
provides that pharmacists, in order to not endanger their
reimbursement by the health insurer, must take account of these
rebate agreements. The section puts pharmacists under the
obligation to dispense the cheapest drug to an insured patient unless
the doctor`s prescription explicitly orders to provide a specific brand
by striking out the “aut idem” field. This is referred to as the
“automatic substitution rule.” By budget control, doctors on the
other hand are motivated to leave the “aut idem” field on their
prescriptions and, consequently, allow substitution.16
B. Decision and Reasoning
The Regional Court of Hamburg found that the defendants
indirectly infringed the second medical use claim by signing the
rebate agreement without explicitly carving out the use to treat pain
and by providing Pregabalin to pharmacies in the course of the
agreement.17 With respect to the regulatory environment, it was
found to be manifestly clear that the defendants provided the
Pregabalin for a later use to treat pain.
As shown above other German courts have limited the use of a
Swiss-type second medical use claim to a manifest arrangement that
can be closely linked to the confectioning of the product or its
packaging. Though the Regional Court raised the question whether
the concept of manifest arrangement is to be applied to the test of
indirect infringement at all. However, the court left this question
open by finding that the products subject to the rebate agreements
were already confectioned and ready to be used for the treatment of
pain. The purpose, the court claimed, was added by the pharmacist
2 April 2015 – 327 O 67/15; BeckRS 2015, 08240; GRUR-RR 2015, 330;
appeal is pending, an oral hearing is scheduled for July 28, 2016.
16
2 April 2015 – 327 O 67/15; BeckRS 2015, 08240; GRUR-RR 2015, 330;
appeal is pending, an oral hearing is scheduled for July 28, 2016.
17
2 April 2015 – 327 O 67/15; BeckRS 2015, 08240; GRUR-RR 2015, 330;
appeal is pending, an oral hearing is scheduled for July 28, 2016.
15
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due to the automatic substitution; and it is obvious that the products
offered and supplied under the rebate agreements will also be used
in the patented indication to treat pain given the regulatory/social
law environment. Carving-out and skinny labelling do not exclude
indirect patent infringement if the rebate agreement is not limited to
non-patented indications. The obligation under social law to
dispense a substitute does not justify an infringement of the patent,
as patent law requirements must be respected at all times.
II. OTHER DECISIONS
In the context of the legal disputes which led to the Hamburg
decision, the Hannover Social Court18 and the 2nd Federal
Procurement Chamber of the Federal Cartel Office19 each granted
preliminary injunctions against a health insurer based on public
procurement law only, requiring the insurer not to enter into such
rebate agreements and not to close such tenders respectively, as they
are not in line with patent law. The details of the Hamburg patent
law discussion were left basically untouched. Parallel patent
litigation in other European courts showed mixed results20.
CONCLUSION
Until the Regional Court of Hamburg`s decision, the belief
existed that an indirect infringement of a Swiss-type second medical
use claim encompassed actions such as providing a not-yet
manifestly arranged drug to a customer in order to allow the
customers to later manifestly arrange that drug for the second
medical use. All intended activities by the customer aimed at the
direct use of the drug rather than the manifest arrangement would
not constitute indirect patent infringement by the manufacturer. If
the Hamburg decisions are confirmed by the higher courts21,
14 September 2015 – S 2 KR 374/15 ER.
16 March 2015 – VK2 – 7/15; VPRRS 2015, 0147.
20
See footnote no. 1.
21
Which is however kind of unlikely due to the procedural circumstances as 4
out of 5 parallel preliminary injunctions have by now become final as the
defendants have accepted them. Only one appeal is still pending before the
18
19
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however, this understanding of the concept of manifest arrangement
would require modification. Currently, this understanding only
provides a way to find direct patent infringement in a manifest
arrangement, but no way to find indirect infringement in cases
where the product itself or its packaging is neutral but other
circumstances—as in the case decided in Hamburg—manifestly
indicate the intention of the later use for the second indication. It has
to be seen if the recent “Pemetrexed-decision22 shows a way out of
this dilemma. The Federal Court of Justice has indicated in that
decision that a Swiss-type claim may provide the same purpose
limited substance protection as a purpose limited substance claim
does. The finding is however not final as the case has been sent back
to the lower court for further consideration.
PRACTICE POINTERS
•

Skinny labeling and carving-out may no longer provide a safe
harbor for competing pharmaceutical companies.

•

Competing pharmaceutical companies are strongly advised to
enter into rebate agreements only if any patented second medical
uses are explicitly carved out.

•

Health insurers are strongly advised to respect patent law in
public tenders and rebate agreements, as social conventions no
longer provide an excuse to disregard patent law.

Hamburg Higher Regional Court (case no. 3 U 91/15). The oral hearing has
been postponed from July 2016 to February 2017 to await the outcome of
pending nullity proceedings.
22
Federal Court of Justice IBRR3 2016, 1909 – Pemetrexed [#85-88].
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